Review
doi: 10.1111/j.1365-2141.2010.08139.x.
Epub 2010 Mar 11.
A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A
Affiliations
- PMID: 20230411
- DOI: 10.1111/j.1365-2141.2010.08139.x
Item in Clipboard
Review
A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A
Br J Haematol.
2010 May.
Abstract
Consensus-based guidelines supported by the literature are presented on the role of prophylactic administration of factor VIII concentrate in children and adults with severe haemophilia A. The timing of initiation of prophylaxis, the choice of prophylactic regimen, monitoring, management of breakthrough bleeding and education of the patient and family are discussed.
Similar articles
-
Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.Haemophilia. 2008 Jul;14(4):671-84. doi: 10.1111/j.1365-2516.2008.01695.x. Epub 2008 Apr 4. Haemophilia. 2008. PMID: 18422612
-
Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.Haemophilia. 2013 Jan;19(1):27-34. doi: 10.1111/j.1365-2516.2012.02926.x. Haemophilia. 2013. PMID: 23231016
-
Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.Haemophilia. 2009 Sep;15(5):1014-21. doi: 10.1111/j.1365-2516.2009.02036.x. Epub 2009 Jun 1. Haemophilia. 2009. PMID: 19493018
-
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Br J Haematol. 2006 Jun;133(6):591-605. doi: 10.1111/j.1365-2141.2006.06087.x. Br J Haematol. 2006. PMID: 16704433 Review.
-
Current issues in prophylactic therapy for persons with hemophilia.Acta Haematol. 2006;115(3-4):162-71. doi: 10.1159/000090930. Acta Haematol. 2006. PMID: 16549891 Review.
Cited by
-
Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A.Res Pract Thromb Haemost. 2023 Jan 12;7(1):100005. doi: 10.1016/j.rpth.2022.100005. eCollection 2023 Jan. Res Pract Thromb Haemost. 2023. PMID: 36891521 Free PMC article.
-
Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.Haematologica. 2015 Mar;100(3):e84-6. doi: 10.3324/haematol.2014.115709. Epub 2014 Dec 19. Haematologica. 2015. PMID: 25527565 Free PMC article. No abstract available.
-
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.Blood. 2013 Aug 15;122(7):1129-36. doi: 10.1182/blood-2012-12-470898. Epub 2013 Jun 18. Blood. 2013. PMID: 23777770 Free PMC article.
-
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions.BMC Hematol. 2015 Feb 14;15:4. doi: 10.1186/s12878-015-0022-8. eCollection 2015. BMC Hematol. 2015. PMID: 25692030 Free PMC article.
-
[HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy].Zhonghua Xue Ye Xue Za Zhi. 2018 Oct 14;39(10):817-821. doi: 10.3760/cma.j.issn.0253-2727.2018.10.006. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369202 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
